



For immediate release September 9, 2013

Genovis' subsidiary GeccoDots introduces groundbreaking product and presents pipeline project results

On September 17 GeccoDots will launch a new product intended for the preclinical market for medical imaging. The launch will occur at WMIC* in Savannah, Georgia, USA. At the same time, new results from the Nanomotus project and the Sentinel Node project will be presented at the scientific portion of the conference.

"It feels great to get started with commercial development at GeccoDots, at the same time that we are proud that, together with our cooperative partners, we can present exciting new results from our development projects," says Sarah Fredriksson, CEO of GeccoDots AB.

The new product is a nanoparticle that serves as a contrast agent in magnetic resonance imaging, PET/SPECT, optical imaging and ultrasound. It is packaged in an extremely easy-to-use kit and takes less than 30 minutes to prepare. A single nanoparticle can be used in several different imaging techniques. The technology paves the way for comparative and supplementary studies using different imaging techniques, known as multimodal imaging, without needing to switch contrast agents. The product is being launched under the FeoDot Easy Label brand.

For additional information please contact:

Sarah Fredriksson, CEO of Genovis AB

Tel: +46 (0)46-10 12 35

e-mail: sarah.fredriksson@genovis.com

ABOUT GENOVIS

Genovis' business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis develops and sells unique enzymes (protein engineering portfolio) in innovative product formats that facilitate development and quality control of and biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging.

Genovis shares are listed on NASDAQ OMX First North, and Thenberg Fondkommission is Certified Adviser for the Company, t: +46 (0)31-745 50 00

**The World Molecular Imaging Congress (WMIC) 2013 will feature new advancements in molecular multimodal imaging with a focus on discovery, pre-clinical and translational research, highlighting first-in-human studies that drive innovative diagnostics and targeted therapy critical to the implementation of precision medicine. This year's program will consist of 168 oral presentations and 35 spotlight presentations emphasizing five categories: Chemistry & Imaging Probes, First-in-Human & Clinical Studies, Preclinical Cell & Tissue Level Studies, Preclinical in vivo Studies, Technology & Software development, with more than 60 top Industry Exhibitors. Visit www.wmicmeeting.org.*